Malignant pleural effusion (MPE) is one of the most common metastases in Non-Small Cell Lung Carcinoma (NSCLC). Some part of the pleural fluid analysis affects the patient's survival. A retrospective cohort study using medical record data of 76 patients was done in Prof. Dr. IGNG Ngoerah General Hospital. The one-year survival was 36.6%, with a median survival of 240 days or 8 months (95% CI 110.94–369.05). The cut-off point for pleural fluid protein was 5 g/dL (sensitivity 33.3%, specificity 32.1%), glucose 47.5 mg/dL (sensitivity 81.3%, specificity 32.1%), lactate dehydrogenase (LDH) 978.5 IU/L (sensitivity 41.7%, specificity 46.4%) and pH 7.3 (sensitivity 62.5%, specificity 35.7%). Bivariate analysis showed that only protein was associated with survival. Protein < 5 g/dL had a median survival of 116 days (95% CI 67.96 – 164.05, p = 0.001). Multivariate analysis showed pleural fluid protein < 5gr dL, best supportive care therapy, and non-adenocarcinoma histology were independent risk factors for death {HR 2,345,95% CI: 1,055-5,214; p= 0.037; HR 5,332. 95% CI: 2.109 – 13.478; p = 0.000; HR 2,635, 95% CI 1,096 – 6,335; p = 0.30).